Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 02, 2022 12:30 ET | Source: Molecular Partners

Molecular Partners Announces Upcoming Participation in Investor and Scientific Conferences

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
October 27, 2022 16:00 ET | Source: Molecular Partners

Interim Management Statement Q3 2022: Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-End

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
October 27, 2022 16:00 ET | Source: Molecular Partners

Molecular Partners Announces Planned Departure of Chief Financial Officer

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
August 25, 2022 16:30 ET | Source: Molecular Partners

Molecular Partners Reports Corporate Highlights and H1 2022 Financials

Continued development of MP0317, with initial clinical data from Phase 1 study expected in the second half of 2022Initiation of Phase 1 study for MP0533 expected by year endContinued progression of...
August 18, 2022 01:00 ET | Source: Molecular Partners

Molecular Partners Half Year 2022 News Release and Investor Call Details

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
July 21, 2022 11:30 ET | Source: Molecular Partners

Molecular Partners Announces Publication in Nature Biotechnology Detailing Design and Mechanism of Ensovibep DARPin Antiviral for SARS-CoV-2

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
June 10, 2022 01:00 ET | Source: Molecular Partners

Molecular Partners Announces Participation in Scientific Conferences

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
May 12, 2022 16:05 ET | Source: Molecular Partners

Interim Management Statement Q1 2022 of Molecular Partners: Cash Runway into 2026 and Portfolio Progress Highlight Strategic Momentum

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
May 11, 2022 01:00 ET | Source: Molecular Partners

Molecular Partners to Participate in Upcoming Healthcare Investor Conferences

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 11, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
May 03, 2022 12:00 ET | Source: Molecular Partners

Molecular Partners CEO, Patrick Amstutz, Elected President of the Swiss Biotech Association

BASEL, Switzerland and ZURICH-SCHLIEREN, Switzerland, May 03, 2022 (GLOBE NEWSWIRE) -- The Swiss Biotech Association and Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech...